No serious adverse events were reported and overall tolerability remained favorable in Clearmind Medicine’s second cohort of its Phase I/IIa study of CMND-100 for alcohol use disorder, enabling the independent DSMB to recommend continuation and dose escalation to 80 mg—double the second cohort’s dose.
The review follows completion of treatment for an additional six participants in the second cohort of the multinational, multicenter trial evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate to severe AUD. The second cohort received twice the dose used in the first cohort, and the program now advances to a third cohort at 80 mg per administration. The study is being conducted at sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. CMND-100 is described as a proprietary, non-hallucinogenic neuroplastogen, positioning it apart from hallucinogenic psychedelic approaches currently being explored for substance use disorders.
Strategically, the signal here is less about efficacy and more about operational permission to climb the dose curve quickly. A clean DSMB review at a doubled dose lowers near-term safety risk, supports a more aggressive escalation cadence, and preserves optionality for an earlier go/no-go on dose selection. For a program aiming to decouple neuroplasticity from hallucinatory effects, the ability to reach higher exposures without CNS liabilities is central to both regulatory positioning and commercial viability. It is also an intentional divergence from clinic-intensive psychedelic paradigms that require monitored dosing sessions and psychotherapy, with attendant site burden and cost.
For sites and CROs, a non-hallucinogenic profile—if maintained at higher doses—translates to simpler visit schedules, fewer specialized staff requirements, and potentially broader site network eligibility. That can help in AUD, where recruitment and retention are perennial challenges and operational overhead can derail timelines. The multinational footprint suggests Clearmind is testing feasibility across regulatory environments and standard-of-care backdrops, a prudent step ahead of any randomized expansion that will need harmonized endpoint capture and adherence strategies. For sponsors across the category, the readout underscores a competitive pivot: programs that can deliver neuroplastic effects without intensive monitoring may gain an execution edge and face a lighter REMS or scheduling burden, assuming abuse liability and CNS AE profiles remain benign.
Regulators will ultimately look past tolerability to clinically meaningful reductions in drinking. As the dose increases, exposure–response clarity becomes critical: whether higher doses translate into measurable improvements on accepted endpoints such as no heavy drinking days, reductions in drinks per drinking day, or validated biomarkers like phosphatidylethanol will determine advancement. The multicenter design should also surface practical questions around psychosocial support standardization, PRO fidelity, and handling of concomitant therapies, all of which can complicate signal detection in early AUD studies.
Near-term, the key watch items are completion of the 80 mg cohort, pharmacokinetic linearity and variability at that dose, and any emergent CNS or cardiovascular signals that could cap further escalation. If tolerability holds, expect movement toward an expansion cohort or a randomized Phase IIb with a registrationally aligned endpoint and tighter visit schedules that reflect the non-hallucinogenic mechanism. The unresolved questions are whether CMND-100 can demonstrate durable reductions in heavy drinking without psychotherapy adjuncts, how the effect size will compare to existing agents, and whether operational simplicity can translate into faster, more scalable trials—advantages that could matter as payers and regulators push for real-world practicality alongside efficacy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
